Intramyocardial, Autologous CD34+Cell Therapy for Refractory Angina

被引:376
|
作者
Losordo, Douglas W. [1 ]
Henry, Timothy D. [2 ]
Davidson, Charles
Lee, Joon Sup [3 ]
Costa, Marco A. [4 ]
Bass, Theodore [5 ]
Mendelsohn, Farrell [6 ]
Fortuin, F. David [7 ]
Pepine, Carl J. [8 ]
Traverse, Jay H. [2 ]
Amrani, David [9 ]
Ewenstein, Bruce M. [9 ]
Riedel, Norbert [9 ]
Story, Kenneth [9 ]
Barker, Kerry [9 ]
Povsic, Thomas J. [10 ]
Harrington, Robert A. [10 ]
Schatz, Richard A. [11 ]
机构
[1] Northwestern Univ, NW Mem Hosp, Program Cardiovasc Regenerat Med, Div Cardiol, Chicago, IL 60611 USA
[2] Abbott NW Hosp, Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA
[3] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[4] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA
[5] Shands Jacksonville Med Ctr, Jacksonville, FL USA
[6] Ctr Therapeut Angiogenesis, Birmingham, AL USA
[7] Mayo Clin, Scottsdale, AZ USA
[8] Univ Florida, Gainesville, FL USA
[9] Baxter Healthcare Corp, Deerfield, IL 60015 USA
[10] Duke Univ, Duke Clin Res Inst, Durham, NC USA
[11] Scripps Green Hosp, La Jolla, CA USA
关键词
angiogenesis; endothelial progenitor cells (EPC) myocardial ischemia; myocardial regeneration; stem cells; PERCUTANEOUS CORONARY INTERVENTION; MYOCARDIAL-INFARCTION; UNIVERSAL DEFINITION; CELL TRANSPLANTATION; RANDOMIZED-TRIAL; RESEARCH ISSUES; ARTERY-DISEASE; HEART-DISEASE; DOUBLE-BLIND; ANGIOGENESIS;
D O I
10.1161/CIRCRESAHA.111.245993
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: A growing number of patients with coronary disease have refractory angina. Preclinical and early-phase clinical data suggest that intramyocardial injection of autologous CD34+ cells can improve myocardial perfusion and function. Objective: Evaluate the safety and bioactivity of intramyocardial injections of autologous CD34+ cells in patients with refractory angina who have exhausted all other treatment options. Methods and Results: In this prospective, double-blind, randomized, phase II study (ClinicalTrials.gov identifier: NCT00300053), 167 patients with refractory angina received 1 of 2 doses (1X10(5) or 5X10(5) cells/kg) of mobilized autologous CD34+ cells or an equal volume of diluent (placebo). Treatment was distributed into 10 sites of ischemic, viable myocardium with a NOGA mapping injection catheter. The primary outcome measure was weekly angina frequency 6 months after treatment. Weekly angina frequency was significantly lower in the low-dose group than in placebo-treated patients at both 6 months (6.8 +/- 1.1 versus 10.9 +/- 1.2, P=0.020) and 12 months (6.3 +/- 1.2 versus 11.0 +/- 1.2, P=0.035); measurements in the high-dose group were also lower, but not significantly. Similarly, improvement in exercise tolerance was significantly greater in low-dose patients than in placebo-treated patients (6 months: 139 +/- 151 versus 69 +/- 122 seconds, P=0.014; 12 months: 140 +/- 171 versus 58 +/- 146 seconds, P=0.017) and greater, but not significantly, in the high-dose group. During cell mobilization and collection, 4.6% of patients had cardiac enzyme elevations consistent with non-ST segment elevation myocardial infarction. Mortality at 12 months was 5.4% in the placebo-treatment group with no deaths among cell-treated patients. Conclusions: Patients with refractory angina who received intramyocardial injections of autologous CD34+ cells (10(5) cells/kg) experienced significant improvements in angina frequency and exercise tolerance. The cell-mobilization and -collection procedures were associated with cardiac enzyme elevations, which will be addressed in future studies. (Circ Res. 2011;109:428-436.)
引用
收藏
页码:428 / 436
页数:9
相关论文
共 50 条
  • [21] The CD34+cell concentration in peripheral blood predicts CD34+cell yield in the leukapheresis product
    Hollingsworth, KL
    Zimmerman, TM
    Karrison, T
    Oliver, A
    Williams, SF
    CYTOTHERAPY, 1999, 1 (02) : 141 - 146
  • [22] Autologous haematopoietic stem cell transplantation for refractory Crohn's disease: updating the Milan experience without CD34+cell selection
    Onida, F.
    Cassinotti, A.
    Annaloro, C.
    Della Volpe, A.
    Usardi, P.
    Motta, B.
    Ardizzone, S.
    Tagliaferri, E.
    Porro, G. Bianchi
    Deliliers, G. Lambertenghi
    BONE MARROW TRANSPLANTATION, 2009, 43 : S273 - S273
  • [23] CD34+CELL YIELD ON DAY 1 OF APHERESIS PREDICTS TOTAL CD34+CELL MOBILIZATION, NEUTROPHIL RECOVERY, AND SURVIVAL AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOMA
    Dean, R.
    Rybicki, L.
    Pohlman, B.
    Sweetenham, J.
    Sobecks, R.
    Copelan, E.
    Kalaycio, M.
    Smith, S.
    andresen, S.
    Bolwell, B.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 38 - 38
  • [24] Prediction of CD34+cell yield in haematopoietic cell product in children by peripheral blood CD34+cell count
    Rujkijyanont, P.
    Hipps, J.
    Gan, K.
    Yang, J.
    Wang, C.
    Geiger, T.
    Eldridge, P.
    Leung, W.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S21 - S22
  • [26] HIGHER INTRAMYOCARDIAL HOMING IS ASSOCIATED WITH BETTER CLINICAL RESPONSE TO CD34+CELL THERAPY IN NON-ISCHEMIC DILATED CARDIOMYOPATHY PATIENTS
    Vrtovec, Bojan
    Poglajen, Gregor
    Lezaic, Luka
    Sever, Matjaz
    Haddad, Francois
    Wu, Joseph C.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (10) : E716 - E716
  • [27] INTRACORONARY AUTOLOGOUS CD34+CELL THERAPY FOR TREATMENT OF CORONARY ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH ANGINA AND NON-OBSTRUCTIVE CORONARY ARTERIES: IMPROVE-CED TRIAL
    Corban, Michel
    Toya, Takumi
    Albers, Diana
    Sebaali, Faten
    Bois, John
    Gulati, Rajiv
    Prasad, Abhiram
    Best, Patricia
    Bell, Malcolm
    Rihal, Charanjit
    Prasad, Megha
    Lerman, Lilach
    Solseth, Mary L.
    Winters, Jeffrey L.
    Dietz, Allan B.
    Lerman, Amir
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 3409 - 3409
  • [28] The High CD34+Cell Count in Premobilization Peripheral Blood Predicts an Earlier Start of Leukapheresis and a Sufficient CD34+Cell Yield in Autologous Hematopoietic Stem Cell Transplantation Patients
    Sato, T.
    Watanabe-Okochi, N.
    Masamoto, Y.
    Yoshizato, T.
    Ikeda, T.
    Matsuhashi, M.
    Iino, J.
    Mishima, Y.
    Yoshikawa, N.
    Masuda, A.
    Yatomi, Y.
    Tsuno, H. N.
    Okazaki, H.
    TRANSFUSION, 2014, 54 : 23A - 23A
  • [29] CD34+ Cell Therapy for No-Option Refractory Disabling Angina: Time for FDA Approval?
    Benck, Lillian
    Henry, Timothy D.
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2019, 20 (03) : 177 - 178
  • [30] AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION WITHOUT CD34+CELL SELECTION FOR REFRACTORY CROHN'S DISEASE: THE MILAN EXPERIENCE AFTER 3 YEARS
    Onida, F.
    Cassinotti, A.
    Annaloro, C.
    Ardizzone, S.
    Usardi, P.
    Motta, B.
    Tagliaferri, E.
    Olivares, C.
    Saporiti, G.
    Porro, G. Bianchi
    Deliliers, G. Lambertenghi
    BONE MARROW TRANSPLANTATION, 2010, 45 : S23 - S23